FDA approves Praluent to reduce risk of angina
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Regeneron Pharmaceuticals and Sanofi announced thatThe FDA(http://approved a joint development of the praluent to reduce the risk of heart attack, stroke and heart pain in patients with cardiovascular diseasePraluent is the first PCSK9 inhibitor to meaningfully reduce all-cause mortalityPraluent is the FDA-approved first PCSK9 inhibitor, which helps remove LDL from the blood by inhibiting the binding of PCSK9 to LDL receptors, allowing more LDL receptors to return to the surface of liver cellsThis can help lower LDL levels in the bloodPraluent has been approved in more than 60 countries around the worldIt has been approved by the FDA to help patients with hyperlipidemia reduce LDL-C in combination with a diet, or in combination with other lipid-lowering drugsThis approval is based on Praluent's performance under the name ODYSSEY OUTCOMESIn this randomized double-blind, placebo-controlled multicenter clinicaltrial(http://, 18,924 patients who developed acute coronary artery syndrome (ACS) within a year were treated with Praluent or placeboThese patients are already receiving the maximum dose of statin therapyThe results showed that patients treated with Pauluent had a 15 percent lower risk of major cardiovascular events, a 27 percent lower risk of stroke, a 14 percent lower risk of non-fatal heart attacks, and a 39 percent lower risk of unstable angina requiring hospitalizationAt the same time, the risk of death decreased by 15% in patients
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
